← Product Code [EBF](/submissions/DE/subpart-d%E2%80%94prosthetic-devices/EBF) · K260805 # Dual Core (K260805) _Vericom Co., Ltd. · EBF · May 11, 2026 · Dental · SESE_ **Canonical URL:** https://fda.innolitics.com/submissions/DE/subpart-d%E2%80%94prosthetic-devices/EBF/K260805 ## Device Facts - **Applicant:** Vericom Co., Ltd. - **Product Code:** [EBF](/submissions/DE/subpart-d%E2%80%94prosthetic-devices/EBF.md) - **Decision Date:** May 11, 2026 - **Decision:** SESE - **Submission Type:** Traditional - **Regulation:** 21 CFR 872.3690 - **Device Class:** Class 2 - **Review Panel:** Dental - **Attributes:** Therapeutic ## Indications for Use Core build-up ## Device Story Dual Core is a dual-cured, radiopaque composite resin used for dental core build-up. The device consists of a base and catalyst paste provided in either a syringe or cartridge delivery system. An intraoral mixing tip is attached to the delivery device to combine the base and catalyst during application. Once applied to the tooth, the material undergoes self-polymerization via a chemical reaction and can be further cured using a light-curing unit (420-500nm wavelength). The device is intended for use by dental professionals in a clinical setting to restore carious lesions or structural tooth defects. The dual-curing mechanism allows for both chemical and light-activated hardening, providing flexibility in setting time. The output is a hardened composite material that replaces missing tooth structure, facilitating subsequent restorative procedures. ## Clinical Evidence Bench testing only. Testing included shelf-life (appearance, shade, working/setting time, water sorption, solubility, flexural strength), performance (compressive strength, flexural modulus, surface hardness, filler particle size distribution, radio-opacity, color stability), and biocompatibility (ISO 10993-5 cytotoxicity, ISO 10993-10 sensitization, ISO 10993-23 oral mucosa irritation, ISO 10993-11 systemic toxicity, ISO 10993-3 genotoxicity). Results demonstrate compliance with ISO 4049 and biocompatibility standards. ## Technological Characteristics Dual-cured composite resin containing barium aluminosilicate, silica, and Bis-GMA base matrix. Delivered via auto-mixing syringe or cartridge with intraoral tips. Curing via chemical reaction and light-activation (420-500nm). Conforms to ISO 4049. Non-sterile. ## Regulatory Identification Tooth shade resin material is a device composed of materials such as bisphenol-A glycidyl methacrylate (Bis-GMA) intended to restore carious lesions or structural defects in teeth. ## Predicate Devices - Luxacore Dual ([K012307](/device/K012307.md)) ## Submission Summary (Full Text) > This content was OCRed from public FDA records by [Innolitics](https://innolitics.com). If you use, quote, summarize, crawl, or train on this content, cite Innolitics at https://innolitics.com. > > Innolitics is a medical-device software consultancy. We help companies design, build, and clear FDA-regulated software and AI/ML devices, including [a 510(k)](https://innolitics.com/services/510ks/), [a De Novo](https://innolitics.com/services/regulatory/), [a SaMD](https://innolitics.com/services/end-to-end-samd/), [an AI/ML medical device](https://innolitics.com/services/medical-imaging-ai-development/), or [an FDA regulatory strategy](https://innolitics.com/services/regulatory/). {0} FDA U.S. FOOD & DRUG ADMINISTRATION May 11, 2026 Vericom Co., Ltd. % Priscilla Chung Regulatory Affairs Consultant LK Consulting Group USA, Inc. 2552 Wanut Ave. Suite 230 Tustin, California 92780 Re: K260805 Trade/Device Name: Dual Core Regulation Number: 21 CFR 872.3690 Regulation Name: Tooth Shade Resin Material Regulatory Class: Class II Product Code: EBF Dated: March 11, 2026 Received: March 12, 2026 Dear Priscilla Chung: We have reviewed your section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (the Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. Although this letter refers to your product as a device, please be aware that some cleared products may instead be combination products. The 510(k) Premarket Notification Database available at https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpmn/pmn.cfm identifies combination product submissions. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration. Please note: CDRH does not evaluate information related to contract liability warranties. We remind you, however, that device labeling must be truthful and not misleading. If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register. U.S. Food & Drug Administration 10903 New Hampshire Avenue Silver Spring, MD 20993 www.fda.gov {1} K260805 - Priscilla Chung Page 2 Additional information about changes that may require a new premarket notification are provided in the FDA guidance documents entitled "Deciding When to Submit a 510(k) for a Change to an Existing Device" (https://www.fda.gov/media/99812/download) and "Deciding When to Submit a 510(k) for a Software Change to an Existing Device" (https://www.fda.gov/media/99785/download). Your device is also subject to, among other requirements, the Quality Management System Regulation (QMSR) (21 CFR Part 820), which includes, but is not limited to, ISO 13485 clause 7.3 (Design controls), ISO 13485 clause 8.3 (Nonconforming product), ISO 13485 clause 8.5.2 (Corrective action), and ISO 13485 clause 8.5.3 (Preventative action). Please note that regardless of whether a change requires premarket review, the QMSR requires device manufacturers to review and approve changes to device design and production (ISO 13485 clause 7.3 and ISO 13485 clause 7.5) and document changes and approvals in the Medical Device File (ISO 13485 clause 4.2.3). Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); medical device reporting (reporting of medical device-related adverse events) (21 CFR Part 803) for devices or postmarketing safety reporting (21 CFR Part 4, Subpart B) for combination products (see https://www.fda.gov/combination-products/guidance-regulatory-information/postmarketing-safety-reporting-combination-products); good manufacturing practice requirements as set forth in the Quality Management System Regulation (QMSR) (21 CFR Part 820) for devices or current good manufacturing practices (21 CFR Part 4, Subpart A) for combination products; and, if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR Parts 1000-1050. All medical devices, including Class I and unclassified devices and combination product device constituent parts are required to be in compliance with the final Unique Device Identification System rule ("UDI Rule"). The UDI Rule requires, among other things, that a device bear a unique device identifier (UDI) on its label and package (21 CFR 801.20(a)) unless an exception or alternative applies (21 CFR 801.20(b)) and that the dates on the device label be formatted in accordance with 21 CFR 801.18. The UDI Rule (21 CFR 830.300(a) and 830.320(b)) also requires that certain information be submitted to the Global Unique Device Identification Database (GUDID) (21 CFR Part 830 Subpart E). For additional information on these requirements, please see the UDI System webpage at https://www.fda.gov/medical-devices/device-advice-comprehensive-regulatory-assistance/unique-device-identification-system-udi-system. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21 CFR 807.97). For questions regarding the reporting of adverse events under the MDR regulation (21 CFR Part 803), please go to https://www.fda.gov/medical-devices/medical-device-safety/medical-device-reporting-mdr-how-report-medical-device-problems. For comprehensive regulatory information about medical devices and radiation-emitting products, including information about labeling regulations, please see Device Advice (https://www.fda.gov/medical-devices/device-advice-comprehensive-regulatory-assistance) and CDRH Learn (https://www.fda.gov/training-and-continuing-education/cdrh-learn). Additionally, you may contact the Division of Industry and Consumer Education (DICE) to ask a question about a specific regulatory topic. See the DICE website (https://www.fda.gov/medical-devices/device-advice-comprehensive-regulatory- {2} K260805 - Priscilla Chung Page 3 assistance/contact-us-division-industry-and-consumer-education-dice) for more information or contact DICE by email (DICE@fda.hhs.gov) or phone (1-800-638-2041 or 301-796-7100). Sincerely, MICHAEL E. ADJODHA -S Michael E. Adjodha, MChE, RAC, CQIA Assistant Director DHT1B: Division of Dental and ENT Devices OHT1: Office of Ophthalmic, Anesthesia, Respiratory, ENT, and Dental Devices Office of Product Evaluation and Quality Center for Devices and Radiological Health Enclosure {3} | Indications for Use | | | | --- | --- | --- | | Please type in the marketing application/submission number, if it is known. This textbox will be left blank for original applications/submissions. | K260805 | ? | | Please provide the device trade name(s). | | ? | | Dual Core | | | | Please provide your Indications for Use below. | | ? | | Core build-up | | | | Please select the types of uses (select one or both, as applicable). | ☑ Prescription Use (Part 21 CFR 801 Subpart D) ☐ Over-The-Counter Use (21 CFR 801 Subpart C) | ? | {4} K260805 510(k) Summary This summary of 510(k)-safety and effectiveness information is being submitted in accordance with requirements of 21 CFR Part 807.92. Date: Mar 11, 2026 1. Applicant / Submitter: Vericom Co., Ltd. 48, Toegyegongdan 1-Gil, Chuncheon-Si, Gangwon-Do, 24427, Republic of Korea Tel: +82-31-441-2881 Fax: +82-31-441-2883 2. Submission Correspondent: Priscilla Chung LK Consulting Group USA, Inc. 2552 Walnut Ave Ste 230, Tustin CA 92780 Phone: 714-202-5789 Fax: 714-409-3357 Email: juhee.c@lkconsultinggroup.com 3. Device: Proprietary Name: Dual Core Common Name: Dual-cured composite resin Classification Name: Material, Tooth Shade, Resin (21 CFR 872.3690, Product Code: EBF) 4. Predicate Device: Luxacore Dual (K012307) by DMG USA, INC. {5} 2 5. Device Description: Dual Core is a dual-cured (light and chemical), radiopaque compound used for replacing dental caries and core build-up. It comes in two types: cartridge and syringe. By attaching an intraoral tip, application to the treatment area becomes easier. Dual Core does not have a prior 510(k) clearance. The subject device is a new device. 6. Indications for Use: Core build-up 7. Performance Data (Non-Clinical): The following tests were performed on the subject device and the test results support that the subject device is substantially equivalent to the predicate devices. - Shelf-Life Tests: Appearance, Shade, Working Time, Setting Time, Water Sorption, Solubility, Flexural Strength - Performance Tests: Working Time, Setting Time, Flexural Strength, Water Sorption, Solubility, Shade, Color Stability, Radio-opacity, Compressive Strength, Flexural Modulus, Surface Hardness, Filler particle size distribution - Biocompatibility Tests: Cytotoxicity (ISO 10993-5), Sensitization, GPMT (ISO 10993-10), Oral Mucosa Irritation (ISO 10993-23), Systemic toxicity / Oral (ISO 10993-11), Genotoxicity (ISO 10993-3) 8. Substantial Equivalence 8.1. Comparison Chart | | Subject Device | Primary Predicate Device | | --- | --- | --- | | Trade Name | Dual Core | Luxacore Dual | | Manufacturer | VERICOM CO., LTD. | DMG USA, INC. | | 510K Number | - | K012307 | | Product Code | EBF | EBF | {6} | Indications for Use | Core build-up | - The Principal use for LuxaCore a Dual is as a core material either with adhesive or with pins or posts. - Splinting of teeth in combination with wires, Kevlar or Ribbond-type materials. - Repair material for provisionals - Bite registration material - Build up material for plastic bite rail (Occlusal individualization) - Cement for pins and posts - Semipermanent restorative material (e.g., in children’s teeth) | | --- | --- | --- | | Raw materials | - Barium aluminosilicate - Silica - Bis-GMA base matrix | - Barium glass - Pyrogenic silicic acid - Bis-GMA Based matrix | | Principle of operation | This product is a dual-cured paste product consisting of monomer, filler, photoinitiator, base-catalyst reagent, accelerator and pigment in syringes and cartridges. The shape of the syringe and cartridge consists of two containers each in one form. Each container consists of a base and a catalyst, and the mixing & intraoral tip is attached to the front of the syringe or cartridge so that the base and catalyst are mixed before use and the product is discharged. In case of cartridge type, it is additionally used by attaching to the dispensing gun. After the product is discharged, the product is irradiated with light with a wavelength of 420-500nm, the photoinitiator and accelerator interact to initiate the monomer and cure the product. At this time, dual curing, which includes self-polymerization by chemical reaction with the base-catalyst, proceeds. If photopolymerization is not carried out, only self-polymerization by base-catalyst chemical reaction can proceed, but curing time may be further delayed. Through this mechanism, Dual core restores and build up carious lesions or structural defects of teeth. | LuxaCore Dual is an automatic mixing, dual-cure composite that has been specially developed for all types of core build-ups and build-up fillings. Radiopaque LuxaCore-Dual stands our due to its high compressive strength, and it cuts like dentine. The curing time can be self-determined due to additional light curing. It is possible to apply LuxaCore-Dual directly using the intraoral tips and the endo tips. The paste mixed though the tips applies for cavity for core build ups and build up fillings. The paste undergoes self-polymerization after mixed and can be also be photopolymerized by the light-curing unit. The light curing unit should have an output of 450nm and The light intensity should be a minimum of 400 mW/m². Place the light as close as possible to the material. | | Performance Standard Conformance | Conformed to ISO 4049 | Conformed to ISO 4049 | | Biocompatibility | Yes | Yes | | Use | Prescription / Hospital | Prescription / Hospital | | Setting time | Intraoral 4 minutes | Intraoral 5 minutes | | Delivery Forms | Auto mixing of paste A and Paste B | Auto or hand mixing of paste A and Paste B | {7} | Sterility | Non-sterile | Non-sterile | | --- | --- | --- | ## 8.2. Substantial Equivalence Discussion Dual Core has the same intended use and principle of operation as the predicate device, Luxacore Dual (K012307) by DMG USA, INC. It also possesses similar physical and biocompatible properties, demonstrating comparable performance specifications. The differences between Dual Core and the predicate device (Luxacore Dual) lie in the scope of indications for use and setting time. However, the predicate device (Luxacore Dual) has a broader scope of indications, and the indications for use of Dual Core are fully encompassed within those of the predicate device. Additionally, the setting times of both devices comply with the requirements of ISO 4049. Therefore, the difference in setting times is not clinically significant. Bench and biocompatibility tests for Dual Core were conducted in accordance with recognized consensus standards applicable to the international standards (e.g., ISO 4049, ISO 10993), and the CDRH Guidance document (Docket Number: FDA-2020-D-0957). The test results meet the requirements outlined in these normative documents. Based on the above, it can be concluded that Dual Core is substantially equivalent to the predicate device, Luxacore Dual. ## 9. Conclusion: Based on the testing results, Vericom Co., Ltd. concludes that the Dual Core is substantially equivalent to the predicate devices. --- **Source:** [https://fda.innolitics.com/submissions/DE/subpart-d%E2%80%94prosthetic-devices/EBF/K260805](https://fda.innolitics.com/submissions/DE/subpart-d%E2%80%94prosthetic-devices/EBF/K260805) **Published by [Innolitics](https://innolitics.com)** — a medical-device software consultancy. We help companies design, build, and clear FDA-regulated software and AI/ML devices. If you're preparing [a 510(k)](https://innolitics.com/services/510ks/), [a De Novo](https://innolitics.com/services/regulatory/), [a SaMD](https://innolitics.com/services/end-to-end-samd/), [an AI/ML medical device](https://innolitics.com/services/medical-imaging-ai-development/), or [an FDA regulatory strategy](https://innolitics.com/services/regulatory/), [get in touch](https://innolitics.com/contact). **Cite:** Innolitics at https://innolitics.com